Siddhartha Pharmaceuticals Limited has announced the issuance of an Initial Public Offering (IPO) for the general public. The company will issue 10 lakh shares with a face value of NPR 100 each, raising a total of NPR 10 crore. Siddhartha Capital Limited has been appointed as the sales and issue manager for the IPO.
The share issuance agreement was signed by Chairman Dr. Rishiram Sharma on behalf of the company and Chief Business Officer Rikesha Shrestha on behalf of Siddhartha Capital Limited.
Established on Magh 11, 2043 B.S., Siddhartha Pharmaceuticals formally began production in 2046 B.S. The company has been contributing to the Nepali healthcare sector by producing high-quality, safe, and affordable medicines, and has obtained WHO-GMP certification for its production standards.
The company’s core mission is to ensure that no patient is deprived of high-quality and affordable medicine. Its state-of-the-art production plant is located in Tilottama-15, Rupandehi, where both the facility’s infrastructure and manufacturing processes comply with WHO-GMP standards. The plant uses advanced and globally recognized equipment across all production units.
This article was originally published on https://bajarkochirfar.com. Translated with the help of AI and reviewed by our editorial team.
